ES2274634T3
(es)
*
|
1998-08-29 |
2007-05-16 |
Astrazeneca Ab |
Compuestos de pirimidina.
|
ES2270612T3
(es)
|
1998-08-29 |
2007-04-01 |
Astrazeneca Ab |
Compuestos de pirimidina.
|
GB9828511D0
(en)
|
1998-12-24 |
1999-02-17 |
Zeneca Ltd |
Chemical compounds
|
GB9905075D0
(en)
|
1999-03-06 |
1999-04-28 |
Zeneca Ltd |
Chemical compounds
|
GB9907658D0
(en)
|
1999-04-06 |
1999-05-26 |
Zeneca Ltd |
Chemical compounds
|
GB9919778D0
(en)
|
1999-08-21 |
1999-10-27 |
Zeneca Ltd |
Chemical compounds
|
GB0004886D0
(en)
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
GB0004887D0
(en)
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
GB0004888D0
(en)
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
GB0007371D0
(en)
|
2000-03-28 |
2000-05-17 |
Astrazeneca Uk Ltd |
Chemical compounds
|
GB0016877D0
(en)
|
2000-07-11 |
2000-08-30 |
Astrazeneca Ab |
Chemical compounds
|
GB0021726D0
(en)
|
2000-09-05 |
2000-10-18 |
Astrazeneca Ab |
Chemical compounds
|
DE60128709T2
(de)
*
|
2000-09-15 |
2007-12-27 |
Vertex Pharmaceuticals Inc., Cambridge |
Triazol-verbindungen als protein-kinase-inhibitoren
|
US6660731B2
(en)
|
2000-09-15 |
2003-12-09 |
Vertex Pharmaceuticals Incorporated |
Pyrazole compounds useful as protein kinase inhibitors
|
SI1343782T1
(sl)
|
2000-12-21 |
2009-10-31 |
Smithkline Beecham Corp |
Pirimidinamini kot modulatorji angiogeneze
|
AU3113902A
(en)
|
2000-12-21 |
2002-07-01 |
Bristol Myers Squibb Co |
Thiazolyl inhibitors of tec family tyrosine kinases
|
KR100947185B1
(ko)
*
|
2000-12-21 |
2010-03-15 |
버텍스 파마슈티칼스 인코포레이티드 |
단백질 키나제 억제제로서 유용한 피라졸 화합물 및 이를 포함하는 조성물
|
GB0103926D0
(en)
*
|
2001-02-17 |
2001-04-04 |
Astrazeneca Ab |
Chemical compounds
|
GB0113041D0
(en)
|
2001-05-30 |
2001-07-18 |
Astrazeneca Ab |
Chemical compounds
|
JP4510442B2
(ja)
*
|
2001-06-26 |
2010-07-21 |
ブリストル−マイヤーズ スクイブ カンパニー |
TNF−α発現のN−ヘテロ環インヒビター
|
US7115617B2
(en)
*
|
2001-08-22 |
2006-10-03 |
Amgen Inc. |
Amino-substituted pyrimidinyl derivatives and methods of use
|
WO2003026665A1
(en)
*
|
2001-09-26 |
2003-04-03 |
Bayer Pharmaceuticals Corporation |
2-phenylamino-4-(5-pyrazolylamino)-pyrimidine derivatives as kinase inhibitors, in particular, src kinase inhibitors
|
ATE407678T1
(de)
|
2001-10-17 |
2008-09-15 |
Boehringer Ingelheim Pharma |
Pyrimidinderivate, arzneimittel enthaltend diese verbindungen, deren verwendung und verfahren zu ihrer herstellung
|
EP1453516A2
(de)
|
2001-10-17 |
2004-09-08 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
5-substituierte 4-amino-2-phenylamino-pyrimdinderivate und ihre verwendung als beta-amyloid modulatoren
|
KR20040062557A
(ko)
*
|
2001-11-01 |
2004-07-07 |
얀센 파마슈티카 엔.브이. |
글리코겐 신타제 키나제 3β 억제제로서의아미노벤즈아미드 유도체
|
SE0104140D0
(sv)
|
2001-12-07 |
2001-12-07 |
Astrazeneca Ab |
Novel Compounds
|
WO2003055489A1
(en)
*
|
2001-12-21 |
2003-07-10 |
Bayer Pharmaceuticals Corporation |
2,4-diamino-pyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
|
TWI329105B
(en)
|
2002-02-01 |
2010-08-21 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidinediamine compounds and their uses
|
GB0205693D0
(en)
|
2002-03-09 |
2002-04-24 |
Astrazeneca Ab |
Chemical compounds
|
GB0205688D0
(en)
*
|
2002-03-09 |
2002-04-24 |
Astrazeneca Ab |
Chemical compounds
|
GB0205690D0
(en)
|
2002-03-09 |
2002-04-24 |
Astrazeneca Ab |
Chemical compounds
|
US7442697B2
(en)
|
2002-03-09 |
2008-10-28 |
Astrazeneca Ab |
4-imidazolyl substituted pyrimidine derivatives with CDK inhibitory activity
|
GB0206215D0
(en)
|
2002-03-15 |
2002-05-01 |
Novartis Ag |
Organic compounds
|
WO2003095448A1
(en)
*
|
2002-05-06 |
2003-11-20 |
Bayer Pharmaceuticals Corporation |
Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders
|
AU2003301758A1
(en)
*
|
2002-05-06 |
2004-05-25 |
Bayer Pharmaceuticals Corporation |
Use of pyrimidine derivates for the manifacture of a medicament for the treatment of hyper-proliferative disorders
|
AU2003265336B8
(en)
|
2002-07-29 |
2009-04-23 |
Rigel Pharmaceuticals, Inc. |
Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
|
CA2494100C
(en)
|
2002-08-02 |
2011-10-11 |
Vertex Pharmaceuticals Incorporated |
Pyrazole compositions useful as inhibitors of gsk-3
|
GEP20084357B
(en)
*
|
2002-12-20 |
2008-04-29 |
Pfizer Prod Inc |
Pyrimidine derivatives for the treatment of abnormal cell growth
|
DE602004021558D1
(de)
*
|
2003-01-17 |
2009-07-30 |
Warner Lambert Co |
2-aminopyridin-substituierteheterocyclen als inhibitoren der zellulären proliferation
|
ES2325440T3
(es)
|
2003-02-20 |
2009-09-04 |
Smithkline Beecham Corporation |
Compuestos de pirimidina.
|
GB0305929D0
(en)
|
2003-03-14 |
2003-04-23 |
Novartis Ag |
Organic compounds
|
GB0311274D0
(en)
|
2003-05-16 |
2003-06-18 |
Astrazeneca Ab |
Chemical compounds
|
GB0311276D0
(en)
|
2003-05-16 |
2003-06-18 |
Astrazeneca Ab |
Chemical compounds
|
PL1656372T3
(pl)
|
2003-07-30 |
2013-08-30 |
Rigel Pharmaceuticals Inc |
Związki 2,4-pirymidynodiaminy do stosowania w leczeniu lub zapobieganiu chorobom autoimmunologicznym
|
PT2287156E
(pt)
|
2003-08-15 |
2013-08-26 |
Novartis Ag |
2,4-di(fenilamino)-pirimidinas úteis no tratamento de doenças neoplásicas, desordens inflamatórias e do sistema imunitário
|
GB0321710D0
(en)
|
2003-09-16 |
2003-10-15 |
Novartis Ag |
Organic compounds
|
CN100494177C
(zh)
*
|
2003-09-18 |
2009-06-03 |
中国医学科学院血液学研究所 |
具有抗肿瘤活性的双酰胺基杂环类衍生物及其制备方法和用途
|
AU2004283137A1
(en)
|
2003-10-17 |
2005-05-06 |
Astrazeneca Ab |
4-(pyrazol-3-ylamino) pyrimidine derivatives for use in the treatment of cancer
|
TW200528101A
(en)
|
2004-02-03 |
2005-09-01 |
Astrazeneca Ab |
Chemical compounds
|
WO2005118543A1
(ja)
*
|
2004-06-03 |
2005-12-15 |
Ono Pharmaceutical Co., Ltd. |
キナーゼ阻害薬およびその用途
|
GB0419161D0
(en)
*
|
2004-08-27 |
2004-09-29 |
Novartis Ag |
Organic compounds
|
US20060047260A1
(en)
*
|
2004-09-02 |
2006-03-02 |
Gregory Ashton |
Absorbent article having a telescoping waist
|
EP1814878B1
(en)
|
2004-11-24 |
2012-01-04 |
Rigel Pharmaceuticals, Inc. |
Spiro-2, 4-pyrimidinediamine compounds and their uses
|
MY169441A
(en)
*
|
2004-12-08 |
2019-04-11 |
Janssen Pharmaceutica Nv |
2,4, (4,6) pyrimidine derivatives
|
EP1828183A1
(en)
*
|
2004-12-17 |
2007-09-05 |
AstraZeneca AB |
4- (4- (imidazol-4-yl) pyrimidin-2-ylamino) benzamides as cdk inhibitors
|
ATE519759T1
(de)
|
2004-12-30 |
2011-08-15 |
Exelixis Inc |
Pyrimidinderivate als kinasemodulatoren und anwendungsverfahren
|
ATE451381T1
(de)
|
2005-01-19 |
2009-12-15 |
Rigel Pharmaceuticals Inc |
Prodrugs aus 2,4-pyrimidindiamin-verbindungen und ihre verwendungen
|
WO2006087530A1
(en)
|
2005-02-16 |
2006-08-24 |
Astrazeneca Ab |
Chemical compounds
|
SI1879573T1
(sl)
|
2005-05-10 |
2013-04-30 |
Incyte Corporation Experimental Station |
Modulatorji indolamin 2,3-dioksigenaze in postopki za uporabo le-te
|
KR20080015409A
(ko)
|
2005-05-16 |
2008-02-19 |
아스트라제네카 아베 |
티로신 키나제 억제제로서 유용한 피라졸릴아미노피리미딘 유도체
|
CA2611312C
(en)
|
2005-06-06 |
2013-12-03 |
Intra-Cellular Therapies, Inc. |
Organic compounds
|
CN105348203B
(zh)
|
2005-06-08 |
2018-09-18 |
里格尔药品股份有限公司 |
抑制jak途径的组合物和方法
|
US20070203161A1
(en)
|
2006-02-24 |
2007-08-30 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
WO2007015064A1
(en)
*
|
2005-07-30 |
2007-02-08 |
Astrazeneca Ab |
Imidazolyl-pyrimidine compounds for use in the treatment of proliferative disorders
|
US20070149506A1
(en)
|
2005-09-22 |
2007-06-28 |
Arvanitis Argyrios G |
Azepine inhibitors of Janus kinases
|
JP2009512636A
(ja)
*
|
2005-09-30 |
2009-03-26 |
アストラゼネカ アクチボラグ |
細胞増殖抑制作用を有するイミダゾ[1,2−a]ピリジン類
|
JP2009513615A
(ja)
|
2005-10-28 |
2009-04-02 |
アストラゼネカ アクチボラグ |
癌の治療においてチロシンキナーゼ阻害剤として使用するための4−(3−アミノピラゾール)ピリミジン誘導体
|
US8604042B2
(en)
*
|
2005-11-01 |
2013-12-10 |
Targegen, Inc. |
Bi-aryl meta-pyrimidine inhibitors of kinases
|
US8133900B2
(en)
|
2005-11-01 |
2012-03-13 |
Targegen, Inc. |
Use of bi-aryl meta-pyrimidine inhibitors of kinases
|
HUE028987T2
(en)
|
2005-11-01 |
2017-01-30 |
Targegen Inc |
BI-aryl-meta-pyrimidine inhibitors of kinases
|
ES2612196T3
(es)
|
2005-12-13 |
2017-05-12 |
Incyte Holdings Corporation |
Pirrolo[2,3-b]piridinas y pirrolo[2,3-b]pirimidinas sustituidas con heteroarilo como inhibidores de quinasas Janus
|
UA89123C2
(ru)
*
|
2005-12-21 |
2009-12-25 |
Пфайзер Продактс Инк. |
Производные пиримидина для лечения абнормального роста клеток
|
TW200811169A
(en)
*
|
2006-05-26 |
2008-03-01 |
Astrazeneca Ab |
Chemical compounds
|
AU2007269540B2
(en)
|
2006-07-05 |
2013-06-27 |
Exelixis, Inc. |
Methods of using IGF1R and Abl kinase modulators
|
ES2411604T3
(es)
|
2006-11-13 |
2013-07-05 |
Intra-Cellular Therapies, Inc. |
Compuestos orgánicos
|
EP2089034A4
(en)
|
2006-12-05 |
2010-07-28 |
Intra Cellular Therapies Inc |
NEW USES
|
GEP20125691B
(en)
|
2006-12-08 |
2012-11-26 |
Irm Llc |
Compounds and compositions as protein kinase inhibitors
|
JP5208123B2
(ja)
*
|
2006-12-08 |
2013-06-12 |
アイアールエム・リミテッド・ライアビリティ・カンパニー |
タンパク質キナーゼ阻害剤としての化合物および組成物
|
WO2008079965A1
(en)
|
2006-12-22 |
2008-07-03 |
Incyte Corporation |
Substituted heterocycles as janus kinase inhibitors
|
FR2911138B1
(fr)
*
|
2007-01-05 |
2009-02-20 |
Sanofi Aventis Sa |
Nouveaux derives de n, n'-2,4-dianilinopyrimidines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
|
WO2008118823A2
(en)
*
|
2007-03-26 |
2008-10-02 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
DK2154967T5
(en)
*
|
2007-04-16 |
2014-11-17 |
Hutchison Medipharma Entpr Ltd |
Pyriminderivater
|
UA99459C2
(en)
|
2007-05-04 |
2012-08-27 |
Астразенека Аб |
9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
|
EP2173752B2
(en)
|
2007-06-13 |
2022-07-13 |
Incyte Holdings Corporation |
Salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
|
CL2008001709A1
(es)
|
2007-06-13 |
2008-11-03 |
Incyte Corp |
Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
|
AU2008296545B2
(en)
|
2007-08-28 |
2011-09-29 |
Irm Llc |
2 -biphenylamino-4 -aminopyrimidine derivatives as kinase inhibitors
|
BRPI0820544A2
(pt)
|
2007-11-16 |
2015-06-16 |
Incyte Corp |
4-pirazolil-n-arilpirimidin-2-aminas e pirazolil-n-heteroarilpirimidin-2-aminas como inibidores de janus cinase
|
KR20120108042A
(ko)
|
2008-03-11 |
2012-10-04 |
인사이트 코포레이션 |
Jak 억제제로서의 아제티딘 및 시클로부탄 유도체
|
EP2274288A2
(en)
|
2008-04-24 |
2011-01-19 |
Incyte Corporation |
Macrocyclic compounds and their use as kinase inhibitors
|
AU2009261764B2
(en)
*
|
2008-06-17 |
2013-01-10 |
Astrazeneca Ab |
Pyridine compounds
|
US8445505B2
(en)
|
2008-06-25 |
2013-05-21 |
Irm Llc |
Pyrimidine derivatives as kinase inhibitors
|
UY31929A
(es)
|
2008-06-25 |
2010-01-05 |
Irm Llc |
Compuestos y composiciones como inhibidores de cinasa
|
KR20110020940A
(ko)
*
|
2008-06-25 |
2011-03-03 |
아이알엠 엘엘씨 |
키나제 억제제로서의 피리미딘 유도체
|
KR101892989B1
(ko)
|
2008-06-27 |
2018-08-30 |
셀젠 카르 엘엘씨 |
헤테로아릴 화합물 및 이의 용도
|
US8338439B2
(en)
|
2008-06-27 |
2012-12-25 |
Celgene Avilomics Research, Inc. |
2,4-disubstituted pyrimidines useful as kinase inhibitors
|
US11351168B1
(en)
|
2008-06-27 |
2022-06-07 |
Celgene Car Llc |
2,4-disubstituted pyrimidines useful as kinase inhibitors
|
NO2824100T3
(es)
|
2008-07-08 |
2018-07-21 |
|
|
CL2009001884A1
(es)
|
2008-10-02 |
2010-05-14 |
Incyte Holdings Corp |
Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
|
AR074210A1
(es)
*
|
2008-11-24 |
2010-12-29 |
Boehringer Ingelheim Int |
Derivados de pirimidina como inhibidores de ptk2-quinasa
|
TW201024281A
(en)
|
2008-11-24 |
2010-07-01 |
Boehringer Ingelheim Int |
New compounds
|
WO2010085597A1
(en)
|
2009-01-23 |
2010-07-29 |
Incyte Corporation |
Macrocyclic compounds and their use as kinase inhibitors
|
JP2012518685A
(ja)
|
2009-02-25 |
2012-08-16 |
イントラ−セルラー・セラピーズ・インコーポレイテッド |
眼障害のためのpde1阻害剤
|
WO2010129053A2
(en)
|
2009-05-05 |
2010-11-11 |
Dana Farber Cancer Institute |
Egfr inhibitors and methods of treating disorders
|
JP2012526810A
(ja)
|
2009-05-13 |
2012-11-01 |
イントラ−セルラー・セラピーズ・インコーポレイテッド |
有機化合物
|
TWI484962B
(zh)
|
2009-05-22 |
2015-05-21 |
Incyte Corp |
作為jak抑制劑之3-〔4-(7h-吡咯并〔2,3-d〕嘧啶-4-基)-1h-吡唑-1-基〕辛烷或庚腈
|
US8716303B2
(en)
|
2009-05-22 |
2014-05-06 |
Incyte Corporation |
N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
|
TW201100441A
(en)
|
2009-06-01 |
2011-01-01 |
Osi Pharm Inc |
Amino pyrimidine anticancer compounds
|
AU2010273816B2
(en)
|
2009-06-29 |
2015-07-09 |
Incyte Holdings Corporation |
Pyrimidinones as PI3K inhibitors
|
US9249145B2
(en)
|
2009-09-01 |
2016-02-02 |
Incyte Holdings Corporation |
Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
|
EP2486041B1
(en)
|
2009-10-09 |
2013-08-14 |
Incyte Corporation |
Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
|
WO2011075630A1
(en)
|
2009-12-18 |
2011-06-23 |
Incyte Corporation |
Substituted fused aryl and heteroaryl derivatives as pi3k inhibitors
|
WO2011075643A1
(en)
|
2009-12-18 |
2011-06-23 |
Incyte Corporation |
Substituted heteroaryl fused derivatives as pi3k inhibitors
|
US20110207754A1
(en)
|
2010-02-18 |
2011-08-25 |
Incyte Corporation |
Cyclobutane and methylcyclobutane derivatives as janus kinase inhibitors
|
KR102354472B1
(ko)
|
2010-03-10 |
2022-01-21 |
인사이트 홀딩스 코포레이션 |
Jak1 저해제로서의 피페리딘4일 아제티딘 유도체
|
WO2011130342A1
(en)
|
2010-04-14 |
2011-10-20 |
Incyte Corporation |
FUSED DERIVATIVES AS ΡI3Κδ INHIBITORS
|
JP5607241B2
(ja)
|
2010-05-21 |
2014-10-15 |
ケミリア・エービー |
新規ピリミジン誘導体
|
EP2574168B9
(en)
|
2010-05-21 |
2016-10-05 |
Incyte Holdings Corporation |
Topical formulation for a jak inhibitor
|
US9062055B2
(en)
|
2010-06-21 |
2015-06-23 |
Incyte Corporation |
Fused pyrrole derivatives as PI3K inhibitors
|
CA2807051A1
(en)
|
2010-08-10 |
2012-02-16 |
Celgene Avilomics Research, Inc. |
Besylate salt of a btk inhibitor
|
US8975249B2
(en)
|
2010-11-01 |
2015-03-10 |
Celgene Avilomics Research, Inc. |
Heterocyclic compounds and uses thereof
|
US9238629B2
(en)
|
2010-11-01 |
2016-01-19 |
Celgene Avilomics Research, Inc. |
Heteroaryl compounds and uses thereof
|
CA2816957A1
(en)
|
2010-11-07 |
2012-05-10 |
Targegen, Inc. |
Compositions and methods for treating myelofibrosis
|
JP5957003B2
(ja)
|
2010-11-10 |
2016-07-27 |
セルジーン アヴィロミクス リサーチ, インコーポレイテッド |
変異体選択的egfr阻害剤およびその使用
|
WO2012068450A1
(en)
|
2010-11-19 |
2012-05-24 |
Incyte Corporation |
Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
|
JP5917544B2
(ja)
|
2010-11-19 |
2016-05-18 |
インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation |
Jak阻害剤としての複素環置換ピロロピリジンおよびピロロピリミジン
|
JP6000273B2
(ja)
*
|
2010-11-29 |
2016-09-28 |
オーエスアイ・ファーマシューティカルズ,エルエルシー |
大環状キナーゼ阻害剤
|
EP2655374B1
(en)
|
2010-12-20 |
2019-10-23 |
Incyte Holdings Corporation |
N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors
|
EP2675793B1
(en)
|
2011-02-17 |
2018-08-08 |
Cancer Therapeutics Crc Pty Limited |
Fak inhibitors
|
CN103534240B
(zh)
|
2011-02-17 |
2015-12-09 |
癌症疗法Crc私人有限公司 |
选择性fak抑制剂
|
CA2827673C
(en)
|
2011-02-18 |
2020-10-27 |
Novartis Pharma Ag |
Mtor/jak inhibitor combination therapy
|
WO2012125629A1
(en)
|
2011-03-14 |
2012-09-20 |
Incyte Corporation |
Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
|
US9006241B2
(en)
|
2011-03-24 |
2015-04-14 |
Noviga Research Ab |
Pyrimidine derivatives
|
US9126948B2
(en)
|
2011-03-25 |
2015-09-08 |
Incyte Holdings Corporation |
Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
|
US9249124B2
(en)
|
2011-03-30 |
2016-02-02 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Aurora kinase inhibitors and methods of making and using thereof
|
JP5876146B2
(ja)
|
2011-06-20 |
2016-03-02 |
インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation |
Jak阻害剤としてのアゼチジニルフェニル、ピリジル、またはピラジニルカルボキサミド誘導体
|
US9358229B2
(en)
|
2011-08-10 |
2016-06-07 |
Novartis Pharma Ag |
JAK PI3K/mTOR combination therapy
|
TW201313721A
(zh)
|
2011-08-18 |
2013-04-01 |
Incyte Corp |
作為jak抑制劑之環己基氮雜環丁烷衍生物
|
AR087760A1
(es)
|
2011-09-02 |
2014-04-16 |
Incyte Corp |
Heterociclilaminas como inhibidores de pi3k
|
UA111854C2
(uk)
|
2011-09-07 |
2016-06-24 |
Інсайт Холдінгс Корпорейшн |
Способи і проміжні сполуки для отримання інгібіторів jak
|
TW201325593A
(zh)
|
2011-10-28 |
2013-07-01 |
Celgene Avilomics Res Inc |
治療布魯頓(bruton’s)酪胺酸激酶疾病或病症之方法
|
KR102090453B1
(ko)
|
2012-03-15 |
2020-03-19 |
셀젠 카르 엘엘씨 |
상피 성장 인자 수용체 키나제 억제제의 염
|
SG11201405691WA
(en)
|
2012-03-15 |
2014-10-30 |
Celgene Avilomics Res Inc |
Solid forms of an epidermal growth factor receptor kinase inhibitor
|
AR090548A1
(es)
|
2012-04-02 |
2014-11-19 |
Incyte Corp |
Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
|
AR091079A1
(es)
|
2012-05-18 |
2014-12-30 |
Incyte Corp |
Derivados de pirrolopirimidina y pirrolopiridina sustituida con piperidinilciclobutilo como inhibidores de jak
|
SG10201610416TA
(en)
|
2012-06-13 |
2017-01-27 |
Incyte Corp |
Substituted tricyclic compounds as fgfr inhibitors
|
SG10201703533VA
(en)
|
2012-11-01 |
2017-06-29 |
Incyte Corp |
Tricyclic fused thiophene derivatives as jak inhibitors
|
HUE055894T2
(hu)
|
2012-11-15 |
2021-12-28 |
Incyte Holdings Corp |
A ruxolitinib nyújtott felszabadulású dózisformái
|
US9126950B2
(en)
|
2012-12-21 |
2015-09-08 |
Celgene Avilomics Research, Inc. |
Heteroaryl compounds and uses thereof
|
CN103059030B
(zh)
*
|
2012-12-28 |
2015-04-29 |
北京师范大学 |
一种具有粘着斑激酶抑制作用的嘧啶类化合物及其制备方法和应用
|
US9561228B2
(en)
|
2013-02-08 |
2017-02-07 |
Celgene Avilomics Research, Inc. |
ERK inhibitors and uses thereof
|
US9801882B2
(en)
|
2013-02-17 |
2017-10-31 |
Intra-Cellular Therapies, Inc. |
Phosphodiesterase-1 inhibitors and their use in treatment of cardiovascular diseases
|
TWI736135B
(zh)
|
2013-03-01 |
2021-08-11 |
美商英塞特控股公司 |
吡唑并嘧啶衍生物治療PI3Kδ相關病症之用途
|
PE20151902A1
(es)
|
2013-03-06 |
2015-12-26 |
Incyte Corp |
Proceso e intermedios para hacer un inhibidor de jak
|
JP2016518343A
(ja)
|
2013-03-15 |
2016-06-23 |
イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. |
新規使用
|
DK2970279T3
(da)
|
2013-03-15 |
2020-11-30 |
Intra Cellular Therapies Inc |
Organiske forbindelser
|
SI2986610T1
(en)
|
2013-04-19 |
2018-04-30 |
Incyte Holdings Corporation |
Bicyclic heterocycles as inhibitors of FGFR
|
SI3527263T1
(sl)
|
2013-05-17 |
2021-05-31 |
Incyte Corporation |
Derivati bipirazola kot zaviralci JAK
|
EP3721873A1
(en)
|
2013-08-07 |
2020-10-14 |
Incyte Corporation |
Sustained release dosage forms for a jak1 inhibitor
|
SG11201601119XA
(en)
|
2013-08-20 |
2016-03-30 |
Incyte Corp |
Survival benefit in patients with solid tumors with elevated c-reactive protein levels
|
US9492471B2
(en)
|
2013-08-27 |
2016-11-15 |
Celgene Avilomics Research, Inc. |
Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
|
US9415049B2
(en)
|
2013-12-20 |
2016-08-16 |
Celgene Avilomics Research, Inc. |
Heteroaryl compounds and uses thereof
|
PL3110409T3
(pl)
|
2014-02-28 |
2018-12-31 |
Incyte Corporation |
Inhibitory jak1 do leczenia zespołów mielodysplastycznych
|
UA119767C2
(uk)
|
2014-04-08 |
2019-08-12 |
Інсайт Корпорейшн |
Лікування b-клітинних злоякісних новоутворень із застосуванням комбінації інгібіторів jak та pi3k
|
TW201625643A
(zh)
|
2014-04-30 |
2016-07-16 |
英塞特公司 |
製備jak1抑制劑之方法及其新形式
|
WO2015184305A1
(en)
|
2014-05-30 |
2015-12-03 |
Incyte Corporation |
TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
|
US10077277B2
(en)
|
2014-06-11 |
2018-09-18 |
Incyte Corporation |
Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
|
DK3157926T3
(da)
|
2014-06-20 |
2019-08-19 |
Intra Cellular Therapies Inc |
Organiske forbindelser
|
US10285992B2
(en)
|
2014-08-07 |
2019-05-14 |
Intra-Cellular Therapies, Inc. |
Combinations of PDE1 inhibitors and NEP inhibitors and associated methods
|
US10131671B2
(en)
|
2014-08-07 |
2018-11-20 |
Intra-Cellular Therapies, Inc. |
Organic compounds
|
US10005760B2
(en)
|
2014-08-13 |
2018-06-26 |
Celgene Car Llc |
Forms and compositions of an ERK inhibitor
|
EP3725789B1
(en)
|
2014-09-17 |
2022-03-09 |
Intra-Cellular Therapies, Inc. |
7,8-dihydro-[2h]-imidazo-[1,2-a]pyrazolo[4,3-e]pyrimidin-4(5h)-one derivatives as phosphodiesterase 1 (pde1) inhibitors for treating diseases, disorders or injuries of the central nervous system (cns)
|
WO2016130501A1
(en)
|
2015-02-09 |
2016-08-18 |
Incyte Corporation |
Aza-heteroaryl compounds as pi3k-gamma inhibitors
|
MA41551A
(fr)
|
2015-02-20 |
2017-12-26 |
Incyte Corp |
Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
|
MX2020004108A
(es)
|
2015-02-20 |
2022-01-03 |
Incyte Corp |
Heterociclos biciclicos como inhibidores de receptores del factor de crecimiento fibroblastico (fgfr).
|
PT3262046T
(pt)
|
2015-02-27 |
2020-12-24 |
Incyte Corp |
Sais de inibidor de pi3k e processos para a sua preparação
|
US9988401B2
(en)
|
2015-05-11 |
2018-06-05 |
Incyte Corporation |
Crystalline forms of a PI3K inhibitor
|
US9732097B2
(en)
|
2015-05-11 |
2017-08-15 |
Incyte Corporation |
Process for the synthesis of a phosphoinositide 3-kinase inhibitor
|
US20160362424A1
(en)
|
2015-05-11 |
2016-12-15 |
Incyte Corporation |
Salts of (s)-7-(1-(9h-purin-6-ylamino)ethyl)-6-(3-fluorophenyl)-3-methyl-5h-thiazolo[3,2-a]pyrimidin-5-one
|
PL3371190T3
(pl)
|
2015-11-06 |
2022-11-07 |
Incyte Corporation |
Związki heterocykliczne jako inhibitory pi3k-gamma
|
ES2833955T3
(es)
|
2016-01-05 |
2021-06-16 |
Incyte Corp |
Piridinas sustituidas con pirazol/imidazol como inhibidores de PI3K-Gamma
|
US11203576B2
(en)
*
|
2016-03-11 |
2021-12-21 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Aurora kinase and Janus kinase inhibitors for prevention of graft versus host disease
|
US10682354B2
(en)
|
2016-03-28 |
2020-06-16 |
Intra-Cellular Therapies, Inc. |
Compositions and methods
|
WO2017223414A1
(en)
|
2016-06-24 |
2017-12-28 |
Incyte Corporation |
HETEROCYCLIC COMPOUNDS AS PI3K-γ INHIBITORS
|
ES2906107T3
(es)
|
2016-09-12 |
2022-04-13 |
Intra Cellular Therapies Inc |
Usos novedosos
|
AR111960A1
(es)
|
2017-05-26 |
2019-09-04 |
Incyte Corp |
Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
|
WO2019079469A1
(en)
|
2017-10-18 |
2019-04-25 |
Incyte Corporation |
CONDENSED IMIDAZOLE DERIVATIVES SUBSTITUTED WITH HYDROXY TERTIARY GROUPS AS INHIBITORS OF PI3K-GAMMA
|
CN107903256B
(zh)
*
|
2017-11-29 |
2019-11-15 |
南方医科大学 |
一种含取代噻唑的2,4-二氨基嘧啶及其应用
|
AR113922A1
(es)
|
2017-12-08 |
2020-07-01 |
Incyte Corp |
Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
|
WO2019126505A1
(en)
|
2017-12-21 |
2019-06-27 |
Incyte Corporation |
3-(5-amino-pyrazin-2-yl)-benzenesulfonamide derivatives and related compounds as pi3k-gamma kinase inhibitors for treating e.g. cancer
|
DK3746429T3
(da)
|
2018-01-30 |
2022-05-02 |
Incyte Corp |
Fremgangsmåder til fremstilling af (1-(3-fluor-2-(trifluormethyl)isonicotinyl)piperidin-4-on)
|
JP7401442B2
(ja)
|
2018-01-31 |
2023-12-19 |
イントラ-セルラー・セラピーズ・インコーポレイテッド |
新規使用
|
BR122023022189A2
(pt)
|
2018-02-16 |
2024-02-20 |
Incyte Corporation |
Usos de inibidores da via de jak1 para o tratamento de distúrbios relacionados a citocinas
|
CR20200441A
(es)
|
2018-02-27 |
2021-03-15 |
Incyte Corp |
Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b
|
PL3762368T3
(pl)
|
2018-03-08 |
2022-06-06 |
Incyte Corporation |
ZWIĄZKI AMINOPIRAZYNODIOLOWE JAKO INHIBITORY PI3K-γ
|
IL277538B1
(en)
|
2018-03-30 |
2024-05-01 |
Incyte Corp |
Use of JAK inhibitors to treat hidradenitis suppurativa
|
US11220510B2
(en)
|
2018-04-09 |
2022-01-11 |
Incyte Corporation |
Pyrrole tricyclic compounds as A2A / A2B inhibitors
|
WO2019213544A2
(en)
|
2018-05-04 |
2019-11-07 |
Incyte Corporation |
Solid forms of an fgfr inhibitor and processes for preparing the same
|
TW201946630A
(zh)
|
2018-05-04 |
2019-12-16 |
美商英塞特公司 |
Fgfr抑制劑之鹽
|
MX2020012376A
(es)
|
2018-05-18 |
2021-03-09 |
Incyte Corp |
Derivados de pirimidina fusionados como inhibidores de los receptores de adenosina a2a/a2b.
|
JP2021525706A
(ja)
|
2018-05-25 |
2021-09-27 |
インサイト・コーポレイションIncyte Corporation |
Sting活性化剤としての三環式複素環式化合物
|
WO2020010003A1
(en)
|
2018-07-02 |
2020-01-09 |
Incyte Corporation |
AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS
|
TW202402759A
(zh)
|
2018-07-05 |
2024-01-16 |
美商英塞特公司 |
作為a2a/a2b抑制劑之稠合吡嗪衍生物
|
US10875872B2
(en)
|
2018-07-31 |
2020-12-29 |
Incyte Corporation |
Heteroaryl amide compounds as sting activators
|
US11008344B2
(en)
|
2018-07-31 |
2021-05-18 |
Incyte Corporation |
Tricyclic heteroaryl compounds as STING activators
|
PT3847175T
(pt)
|
2018-09-05 |
2024-04-16 |
Incyte Corp |
Formas cristalinas de um inibidor da fosfoinositídeo 3-quinase (pi3k)
|
US11066404B2
(en)
|
2018-10-11 |
2021-07-20 |
Incyte Corporation |
Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
|
WO2020102198A1
(en)
|
2018-11-13 |
2020-05-22 |
Incyte Corporation |
Heterocyclic derivatives as pi3k inhibitors
|
US11396502B2
(en)
|
2018-11-13 |
2022-07-26 |
Incyte Corporation |
Substituted heterocyclic derivatives as PI3K inhibitors
|
WO2020102150A1
(en)
|
2018-11-13 |
2020-05-22 |
Incyte Corporation |
Heterocyclic derivatives as pi3k inhibitors
|
US11596692B1
(en)
|
2018-11-21 |
2023-03-07 |
Incyte Corporation |
PD-L1/STING conjugates and methods of use
|
US20220056049A1
(en)
|
2019-01-07 |
2022-02-24 |
Incyte Corporation |
Heteroaryl amide compounds as sting activators
|
TWI829857B
(zh)
|
2019-01-29 |
2024-01-21 |
美商英塞特公司 |
作為a2a / a2b抑制劑之吡唑并吡啶及***并吡啶
|
WO2020168197A1
(en)
|
2019-02-15 |
2020-08-20 |
Incyte Corporation |
Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
|
CA3130210A1
(en)
|
2019-02-15 |
2020-08-20 |
Incyte Corporation |
Cyclin-dependent kinase 2 biomarkers and uses thereof
|
TW202100520A
(zh)
|
2019-03-05 |
2021-01-01 |
美商英塞特公司 |
作為cdk2 抑制劑之吡唑基嘧啶基胺化合物
|
US11628162B2
(en)
|
2019-03-08 |
2023-04-18 |
Incyte Corporation |
Methods of treating cancer with an FGFR inhibitor
|
US11919904B2
(en)
|
2019-03-29 |
2024-03-05 |
Incyte Corporation |
Sulfonylamide compounds as CDK2 inhibitors
|
WO2020223558A1
(en)
|
2019-05-01 |
2020-11-05 |
Incyte Corporation |
Tricyclic amine compounds as cdk2 inhibitors
|
US11440914B2
(en)
|
2019-05-01 |
2022-09-13 |
Incyte Corporation |
Tricyclic amine compounds as CDK2 inhibitors
|
JP2022545568A
(ja)
|
2019-06-10 |
2022-10-27 |
インサイト・コーポレイション |
Jak阻害剤による白斑の局所治療
|
KR20220028075A
(ko)
|
2019-07-03 |
2022-03-08 |
스미토모 다이니폰 파마 온콜로지, 인크. |
티로신 키나제 비-수용체 1 (tnk1) 억제제 및 그의 용도
|
WO2021007269A1
(en)
|
2019-07-09 |
2021-01-14 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
AU2020319875A1
(en)
|
2019-08-01 |
2022-02-17 |
Incyte Corporation |
A dosing regimen for an IDO inhibitor
|
KR20220064369A
(ko)
|
2019-08-14 |
2022-05-18 |
인사이트 코포레이션 |
Cdk2 저해제로서의 이미다졸릴 피리디미딘일아민 화합물
|
CA3150766A1
(en)
|
2019-08-26 |
2021-03-04 |
Incyte Corporation |
Triazolopyrimidines as a2a / a2b inhibitors
|
BR112022006977A2
(pt)
|
2019-10-11 |
2022-09-20 |
Incyte Corp |
Aminas bicíclicas como inibidores de cdk2
|
IL291901A
(en)
|
2019-10-14 |
2022-06-01 |
Incyte Corp |
Bicyclyl heterocycles as fgr suppressors
|
WO2021076124A1
(en)
|
2019-10-16 |
2021-04-22 |
Incyte Corporation |
Use of jak1 inhibitors for the treatment of cutaneous lupus erythematosus and lichen planus (lp)
|
US11566028B2
(en)
|
2019-10-16 |
2023-01-31 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
WO2021113462A1
(en)
|
2019-12-04 |
2021-06-10 |
Incyte Corporation |
Derivatives of an fgfr inhibitor
|
EP4069696A1
(en)
|
2019-12-04 |
2022-10-12 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
CN115697343A
(zh)
|
2020-03-06 |
2023-02-03 |
因赛特公司 |
包含axl/mer和pd-1/pd-l1抑制剂的组合疗法
|
WO2021211864A1
(en)
|
2020-04-16 |
2021-10-21 |
Incyte Corporation |
Fused tricyclic kras inhibitors
|
WO2021231526A1
(en)
|
2020-05-13 |
2021-11-18 |
Incyte Corporation |
Fused pyrimidine compounds as kras inhibitors
|
MX2022015221A
(es)
|
2020-06-02 |
2023-03-08 |
Incyte Corp |
Procesos para preparar un inhibidor de cinasa jano 1 (jak1).
|
US11833155B2
(en)
|
2020-06-03 |
2023-12-05 |
Incyte Corporation |
Combination therapy for treatment of myeloproliferative neoplasms
|
US20220064188A1
(en)
|
2020-08-28 |
2022-03-03 |
Incyte Corporation |
Vinyl imidazole compounds as inhibitors of kras
|
WO2022061351A1
(en)
|
2020-09-16 |
2022-03-24 |
Incyte Corporation |
Topical treatment of vitiligo
|
WO2022072783A1
(en)
|
2020-10-02 |
2022-04-07 |
Incyte Corporation |
Bicyclic dione compounds as inhibitors of kras
|
CN112390760B
(zh)
*
|
2020-10-15 |
2022-07-29 |
北京师范大学 |
靶向fak的化合物及其制备方法和应用
|
IL303238A
(en)
|
2020-12-08 |
2023-07-01 |
Incyte Corp |
Jak1 pathway inhibitors for the treatment of vitiligo
|
WO2022155941A1
(en)
|
2021-01-25 |
2022-07-28 |
Qilu Regor Therapeutics Inc. |
Cdk2 inhibitors
|
WO2022206888A1
(en)
|
2021-03-31 |
2022-10-06 |
Qilu Regor Therapeutics Inc. |
Cdk2 inhibitors and use thereof
|
WO2022221170A1
(en)
|
2021-04-12 |
2022-10-20 |
Incyte Corporation |
Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
|
US11939331B2
(en)
|
2021-06-09 |
2024-03-26 |
Incyte Corporation |
Tricyclic heterocycles as FGFR inhibitors
|
CA3220155A1
(en)
|
2021-06-09 |
2022-12-15 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
US11981671B2
(en)
|
2021-06-21 |
2024-05-14 |
Incyte Corporation |
Bicyclic pyrazolyl amines as CDK2 inhibitors
|
KR20240032915A
(ko)
|
2021-07-07 |
2024-03-12 |
인사이트 코포레이션 |
Kras의 저해제로서의 삼환식 화합물
|
EP4370515A1
(en)
|
2021-07-14 |
2024-05-22 |
Incyte Corporation |
Tricyclic compounds as inhibitors of kras
|
WO2023034290A1
(en)
|
2021-08-31 |
2023-03-09 |
Incyte Corporation |
Naphthyridine compounds as inhibitors of kras
|
US20230151005A1
(en)
|
2021-09-21 |
2023-05-18 |
Incyte Corporation |
Hetero-tricyclic compounds as inhibitors of kras
|
CA3234375A1
(en)
|
2021-10-01 |
2023-04-06 |
Incyte Corporation |
Pyrazoloquinoline kras inhibitors
|
WO2023064857A1
(en)
|
2021-10-14 |
2023-04-20 |
Incyte Corporation |
Quinoline compounds as inhibitors of kras
|
US20230226040A1
(en)
|
2021-11-22 |
2023-07-20 |
Incyte Corporation |
Combination therapy comprising an fgfr inhibitor and a kras inhibitor
|
WO2023102184A1
(en)
|
2021-12-03 |
2023-06-08 |
Incyte Corporation |
Bicyclic amine compounds as cdk12 inhibitors
|
US11976073B2
(en)
|
2021-12-10 |
2024-05-07 |
Incyte Corporation |
Bicyclic amines as CDK2 inhibitors
|
US20230183251A1
(en)
|
2021-12-10 |
2023-06-15 |
Incyte Corporation |
Bicyclic amines as cdk12 inhibitors
|
TW202340215A
(zh)
|
2021-12-22 |
2023-10-16 |
美商英塞特公司 |
Fgfr抑制劑之鹽及固體形式以及其製備方法
|
WO2023116884A1
(en)
|
2021-12-24 |
2023-06-29 |
Qilu Regor Therapeutics Inc. |
Cdk2 inhibitors and use thereof
|
WO2023168686A1
(en)
|
2022-03-11 |
2023-09-14 |
Qilu Regor Therapeutics Inc. |
Substituted cyclopentanes as cdk2 inhibitors
|
US20230279004A1
(en)
|
2022-03-07 |
2023-09-07 |
Incyte Corporation |
Solid forms, salts, and processes of preparation of a cdk2 inhibitor
|
US20230399331A1
(en)
|
2022-06-14 |
2023-12-14 |
Incyte Corporation |
Solid forms of jak inhibitor and process of preparing the same
|
WO2023250430A1
(en)
|
2022-06-22 |
2023-12-28 |
Incyte Corporation |
Bicyclic amine cdk12 inhibitors
|
US20240101557A1
(en)
|
2022-07-11 |
2024-03-28 |
Incyte Corporation |
Fused tricyclic compounds as inhibitors of kras g12v mutants
|
WO2024030600A1
(en)
|
2022-08-05 |
2024-02-08 |
Incyte Corporation |
Treatment of urticaria using jak inhibitors
|